Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03833934 · ADVERSE EVENTS

Adverse events

Study of Plasma NGS for Assessment, Characterization, Evaluation of Patients With ALK Resistance · Source last updated 2025-10-02

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Adverse events occurred during the study; they are not necessarily caused by treatment. Serious events are not interchangeable with severe/grade 3–4 events. These safety populations may differ from efficacy populations.

Collection time frame
Adverse event data not applicable for this study
Other-event reporting threshold
0%

Adverse event data not applicable for this study

Participants affected / participants at risk, as reported
Safety groupSerious eventsOther eventsDeaths
ALK-positive NSCLC With Progression

Patients in this group signed consent, met eligibility criteria, and all had ALK-positive cancer of a primary lung lesion with systemic progression (excluding the central nervous system)

0 / 00 / 00 / 0

Group identifiers: EG000: ALK-positive NSCLC With Progression

Serious adverse events

Event terms and counts are source-reported; expand to read more. A reporting threshold may omit less frequent events.

    Other reported adverse events

    Event terms and counts are source-reported; expand to read more. A reporting threshold may omit less frequent events.

      Complete source fields
      description
      Adverse event data not applicable for this study
      event Groups
      1. deaths Num Affected
        0
        deaths Num At Risk
        0
        description
        Patients in this group signed consent, met eligibility criteria, and all had ALK-positive cancer of a primary lung lesion with systemic progression (excluding the central nervous system)
        id
        EG000
        other Num Affected
        0
        other Num At Risk
        0
        serious Num Affected
        0
        serious Num At Risk
        0
        title
        ALK-positive NSCLC With Progression
      frequency Threshold
      0
      time Frame
      Adverse event data not applicable for this study

      Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

      Preserved source evidence · Not medical advice